Daraxonrasib extends survival in metastatic pancreatic cancer
1. Daraxonrasib is the first-in-class RAS inhibitor approved for metastatic pancreatic adenocarcinoma, addressing a molecular pathway that drives most pancreatic ...
Tag: RAS inhibitor
2MM: Pharma Roundup – mRNA flu vaccine debuts, RAS inhibition extends pancreatic cancer survival, and new therapies advance for dermatomyositis and Tourette syndrome
mFlusiva outperforms standard-dose flu vaccine in adults 50 and older The U.S. Food and Drug Administration (FDA) approved mFlusiva (mRNA-1010) ...
New targeted therapy daraxonrasib improves survival in pancreatic cancer
1. Daraxonrasib significantly improves survival in metastatic pancreatic cancer compared with standard chemotherapy. 2. Strong response rates in combination therapy ...
#VisualAbstract: Continuation of renin–angiotensin system inhibitors does not impact disease progression in those with advanced chronic kidney disease
Click here to read this study in NEJM
Renin-angiotensin system inhibition following transcatheter aortic valve replacement linked with lower cardiac mortality
1. Use of medications to inhibit the renin-angiotensin system (RAS) following transcatheter aortic valve replacement (TAVR) for severe aortic stenosis ...
